CMV Trials In Seronegative Patients Would Need More Preclinical Data
Executive Summary
Human cytomegalovirus vaccine trials in seronegative patients require more preclinical data, FDA's Vaccines & Related Biological Products Advisory Committee concluded Nov. 4.